Recent Development in Clinical Applications of PD-1 and PD-L1 Antibodies for Cancer Immunotherapy

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2017 Dec 3

PMID 29195503

Citations 73

Authors

Bingshan Liu

Yongping Song

Delong Liu

Affiliations

Soon will be listed here.

Abstract

Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy.

Citing Articles

Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023.

Zhang S, Miao L, Tian X, Yang B, Luo B Hum Vaccin Immunother. 2025; 21(1):2440203.

PMID: 39885669 PMC: 11792843. DOI: 10.1080/21645515.2024.2440203.

A case of pembrolizumab-induced toxic epidermal necrolysis with a delayed developmental timeline.

Driscoll W, Yale K, Smith J JAAD Case Rep. 2024; 53:27-29.

PMID: 39435162 PMC: 11491971. DOI: 10.1016/j.jdcr.2024.08.011.

Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I.

Dong H, Wen C, He L, Zhang J, Xiang N, Liang L J Transl Med. 2024; 22(1):769.

PMID: 39143573 PMC: 11325812. DOI: 10.1186/s12967-024-05572-2.

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei.

Li X, Liu G, Wu W Cancers (Basel). 2024; 16(7).

PMID: 38611084 PMC: 11010892. DOI: 10.3390/cancers16071406.

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.

Kurokawa C, Agrawal S, Mitra A, Galvani E, Burke S, Varshine A Mol Ther Oncol. 2024; 32(1):200758.

PMID: 38596304 PMC: 10869731. DOI: 10.1016/j.omton.2023.200758.

References

Ma W, Gilligan B, Yuan J, Li T . Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016; 9(1):47. PMC: 4884396. DOI: 10.1186/s13045-016-0277-y. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Dholaria B, Hammond W, Shreders A, Lou Y . Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016; 9(1):138. PMC: 5148871. DOI: 10.1186/s13045-016-0365-z. View

Heery C, OSullivan-Coyne G, Madan R, Cordes L, Rajan A, Rauckhorst M . Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017; 18(5):587-598. PMC: 6387686. DOI: 10.1016/S1470-2045(17)30239-5. View

Ansell S . Nivolumab in the Treatment of Hodgkin Lymphoma. Clin Cancer Res. 2016; 23(7):1623-1626. DOI: 10.1158/1078-0432.CCR-16-1387. View

Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Annamalai L . PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26):2542-52. PMC: 4927341. DOI: 10.1056/NEJMoa1603702. View

Bellmunt J, Powles T, Vogelzang N . A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev. 2017; 54:58-67. DOI: 10.1016/j.ctrv.2017.01.007. View

Wallin J, Bendell J, Funke R, Sznol M, Korski K, Jones S . Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016; 7:12624. PMC: 5013615. DOI: 10.1038/ncomms12624. View

Alexander P, Wang X . Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. Front Med. 2015; 9(2):134-8. PMC: 4535791. DOI: 10.1007/s11684-015-0396-9. View

10.

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

11.

Foran A, Nadel H, Lee A, Savage K, Deyell R . Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma. J Pediatr Hematol Oncol. 2016; 39(5):e263-e266. DOI: 10.1097/MPH.0000000000000703. View

12.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

13.

Sidaway P . Bladder cancer: Atezolizumab effective against advanced-stage disease. Nat Rev Urol. 2016; 13(5):238. DOI: 10.1038/nrurol.2016.60. View

14.

Younes A, Santoro A, Shipp M, Zinzani P, Timmerman J, Ansell S . Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17(9):1283-94. PMC: 5541855. DOI: 10.1016/S1470-2045(16)30167-X. View

15.

Kantarjian H, Stein A, Gokbuget N, Fielding A, Schuh A, Ribera J . Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017; 376(9):836-847. PMC: 5881572. DOI: 10.1056/NEJMoa1609783. View

16.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

17.

Sidaway P . Bladder cancer: Atezolizumab: an alternative to cisplatin?. Nat Rev Urol. 2016; 14(2):67. DOI: 10.1038/nrurol.2016.271. View

18.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

19.

Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J . Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016; 34(26):3119-25. PMC: 5569690. DOI: 10.1200/JCO.2016.67.9761. View

20.

Reck M, Rabe K . Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):849-861. DOI: 10.1056/NEJMra1703413. View